Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation

André Heeres, Hu Xu (First author), Denise MS van Marion (First author), Femke Hoogstra-Berends, Deli Zhang, Jean-Paul Seerden, Lizette Loen, Herman Steen, Robert H Henning, Bianca J J M Brundel

    Research output: Contribution to journalArticleAcademicpeer-review

    167 Downloads (Pure)

    Abstract

    Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA.

    Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF.
    Original languageEnglish
    Pages (from-to) 345—364
    JournalDrug Design, Development and Therapy
    Volume13
    Publication statusPublished - 18 Jan 2019

    Keywords

    • atrial fibrillation
    • heat shock protein
    • drosophila
    • proteostasis
    • geranylger­anylacetone

    Fingerprint

    Dive into the research topics of 'Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation'. Together they form a unique fingerprint.

    Cite this